Mirco Compagnone
Impact in
- Oncology top 10%
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
-
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Immunology 10
- Immunotherapy and Immune Responses 5
- Immune Cell Function and Interaction 4
-
- Microbial Inactivation Methods 3
- Co-authors
- Angelo PeschiaroliGerry MelinoDoriana FruciLoredana CifaldiLucilla Bongiorno‐BorboneElke MarkertAntonella ConfortiLuigi Aurisicchio
- Journals
- Oncotarget (3 papers)Vaccines (2 papers)Proceedings of the National Academy of Sciences (2 papers)Cell Death Discovery (1 paper)Oncogenesis (1 paper)
- Partner nations
- ItalyUnited StatesUnited Kingdom
In The Last Decade
Mirco Compagnone
23 papers receiving 471 citations
Hit Papers
Peers
Comparison fields: 5 of 65
- Oncology 234
- Immunology 115
- Molecular Biology 296
- Cancer Research 56
- Biotechnology 28
Countries citing papers authored by Mirco Compagnone
This map shows the geographic impact of Mirco Compagnone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirco Compagnone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirco Compagnone more than expected).
Fields of papers citing papers by Mirco Compagnone
This network shows the impact of papers produced by Mirco Compagnone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirco Compagnone. The network helps show where Mirco Compagnone may publish in the future.
Co-authors
The 25 scholars most cited alongside Mirco Compagnone, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy Hit paper breakdown → | 2025 | 25 |
| 2 | 2023 | 4 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 5 | |
| 5 | 2023 | 1 | |
| 6 | 2022 | 21 | |
| 7 | 2022 | 11 | |
| 8 | 2022 | 32 | |
| 9 | 2022 | 3 | |
| 10 | 2021 | 8 | |
| 11 | 2021 | 17 | |
| 12 | 2020 | 34 | |
| 13 | 2019 | 3 | |
| 14 | 2019 | 41 | |
| 15 | 2018 | 22 | |
| 16 | 2017 | 54 | |
| 17 | 2016 | 8 | |
| 18 | 2015 | 37 | |
| 19 | 2015 | 33 | |
| 20 | 2014 | 56 |
About Mirco Compagnone
Mirco Compagnone is a scholar working on Immunology, Biotechnology, Oncology, Infectious Diseases and Animal Science and Zoology, having authored 23 papers that have together received 479 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (5 papers), Immunotherapy and Immune Responses (5 papers), Cancer-related Molecular Pathways (5 papers), Immune Cell Function and Interaction (4 papers), CAR-T cell therapy research (3 papers), Animal Virus Infections Studies (3 papers), Microbial Inactivation Methods (3 papers) and Virus-based gene therapy research (2 papers). The work is most often cited by research in Oncology (234 citations), Immunology (115 citations), Molecular Biology (296 citations), Cancer Research (56 citations) and Biotechnology (28 citations). Mirco Compagnone has collaborated with scholars based in Italy, United States and United Kingdom. Frequent co-authors include Angelo Peschiaroli, Gerry Melino, Doriana Fruci, Loredana Cifaldi, Lucilla Bongiorno‐Borbone, Elke Markert, Antonella Conforti, Luigi Aurisicchio, Veronica Gatti and Arianna Giacobbe. Their work appears in journals such as Oncotarget, Vaccines, Proceedings of the National Academy of Sciences, Cell Death Discovery and Oncogenesis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.